Regional variation in tolvaptan prescribing across England: national data and retrospective evaluation from an expert centre

BACKGROUND: Tolvaptan, a vasopressin V2 receptor antagonist, was approved in 2015 by the UK National Institute for Health and Care Excellence for use in patients with autosomal dominant polycystic kidney disease (ADPKD) and rapid disease progression. Simultaneous guidance was issued by the UK Kidney...

Descripción completa

Detalles Bibliográficos
Autores principales: Chong, Jiehan, Harris, Tess, Ong, Albert C M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9871855/
https://www.ncbi.nlm.nih.gov/pubmed/36726434
http://dx.doi.org/10.1093/ckj/sfac190

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9871855/
https://www.ncbi.nlm.nih.gov/pubmed/36726434
http://dx.doi.org/10.1093/ckj/sfac190

Ejemplares similares